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Abstract
Background: Investigators have hypothesized that omega-3 fatty acid supplementation may modulate the immune
response. However, available evidence is conflicting. We performed this study to investigate the effect of prenatal
eicosapentaenoic acid (EPA)- and docosahexaenoic acid (DHA)-rich fish oil supplementation on maternal and
fetal cytokine production.
Methods: This study is a secondary analysis of a randomized controlled trial designed to assess whether prenatal
EPA- or DHA-rich fish oil supplementation would prevent perinatal depressive symptoms among women at risk. Enrolled
participants received EPA-rich fish oil (1060 mg EPA plus 274 mg DHA), DHA-rich fish oil (900 mg DHA plus 180 mg EPA)
or soy oil placebo. Maternal venous blood was collected at enrollment (12–20 weeks gestation) and after
supplementation (34–36 weeks gestation). Umbilical cord blood was collected at delivery. We analyzed stored
plasma specimens for 16 human cytokines using multiplex immunoassays. Maternal and cord blood cytokine
levels were compared among the treatment groups. Associations of serum DHA and EPA with maternal and
cord blood cytokines were explored via regression analysis.
Results: We enrolled 126 women, of whom 118 completed the trial. Prenatal supplementation with EPA-rich
fish oil significantly lowered maternal IL6, IL15, and TNFα concentrations. However, supplementation with DHA-rich fish oil
had no significant effect on maternal cytokine profiles. Maternal serum DHA fraction was significantly associated with IL1α,
and maternal serum DHA and EPA fractions were significantly associated with IL 10 concentrations after supplementation.
Compared with placebo, supplementation with EPA- or DHA-rich fish oils had no significant effect on cord blood cytokine
concentrations.
Conclusions: Prenatal supplementation with EPA-rich fish oil significantly reduced levels of several inflammatory cytokines
in maternal plasma, while prenatal DHA-rich fish oil had no significant effect on cytokine concentrations. Supplementation
with EPA- and DHA- rich fish oil had no significant effect on umbilical cord blood cytokine concentrations.
Trial registration: Clinical Trial Registration: registration number NCT00711971 7/7/2008.
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Background
Inflammation has been associated with many complica-
tions of pregnancy, including perinatal depression, gesta-
tional diabetes, preterm delivery and preeclampsia [1, 2].
For example, a recent case-control study found that ele-
vated concentrations of TNF- α in mid-pregnancy were
significantly associated with diagnoses of preeclampsia
later in pregnancy, [3] Similarly increases in circulating
IL-1-β, IL-6, IL-18 and TNF have been demonstrated in
women with GDM complicating pregnancy compared
with controls [2]. Likewise, a recent case-control study
of inflammatory markers among subjects with perinatal
depression found that a diagnosis of major depressive
disorder was significantly related to increased concentra-
tions of TNFα [4].
The Western diet has been postulated to be one im-
portant cause of inflammation [5, 6]. Some investigators
have related the increase in inflammatory disorders in
the developed world to an imbalance in dietary intake in
omega-6 to omega-3 fat compared to historical human
diet [7]. Dietary supplementation with omega-3 fatty
acids has therefore been proposed as a mechanism to
potentially reduce inflammation [7].
Omega-3 fatty acids, both in food and through supple-
mentation with fish or algal oil, have long been believed
to limit or modulate the inflammatory response through
modulation of cytokine production. Two early omega-3
fatty acid supplementation studies in healthy adults
using greater than 2.4 g of EPA plus DHA daily reported
significantly reduced blood cytokines TNFα, IL1β, and
IL6 [7–9]. However, a systematic review of randomized
trials using DHA and EPA supplementation among
healthy adults found no consistent effect of supplemen-
tation on blood cytokines [10]. The majority of studies
investigating the effect of dietary supplementation on cy-
tokines have measured cytokines after endotoxin stimu-
lation of cells, whereas, more recent studies have
measured circulating soluble cytokines using multiplex
immunoassays [11]. It is not known whether fish oil sup-
plementation during pregnancy modulates maternal
cytokine production or whether supplementation alters
cytokine concentrations in the umbilical cord blood.
This study is a secondary analysis of a double-blind
randomized control trial carried out to test the hypoth-
esis that EPA- or DHA-rich fish oil supplementation
would reduce perinatal depressive symptoms. A second-
ary aim of the study was to determine the effect of pre-
natal EPA- and DHA- risk fish oil supplementation on
maternal cytokine profiles as well as on cytokines in um-
bilical cord blood [12]. We hypothesized that prenatal
EPA- and DHA-rich fish oil supplementation would re-
duce concentrations of the major pro-inflammatory cy-
tokines IL-β, IL-6, and TNF-α in both maternal and
umbilical cord plasma.
Methods
This study is a planned secondary analysis of plasma
samples that were collected as part of a prospective,
double-blind randomized controlled trial of fish oil sup-
plementation for prevention of depressive symptoms
among pregnant women [12, 13]. To be eligible to par-
ticipate in the parent study, women had to be between
12 and 20 weeks gestation in a singleton pregnancy and
to be at risk for depression based on an Edinburgh Postnatal
Scale Score between 9 and 19 or a past history of depres-
sion. Potential subjects consuming more than two fish meals
per week were not eligible to participate. Subjects were re-
cruited from the antenatal clinics of the University of Mich-
igan Medical Center (Ann Arbor, MI) and St. Joseph Mercy
Health System (Ypsilanti, MI). The overall details of the trial
design have been previously reported [12, 13].
The sample size for the study was determined based
on the expected Beck Depression Inventory scores
among women at risk for depression. The parent study
was designed to detect a 50% reduction in the primary
outcome for the trial, the Beck Depression Inventory
score at 6 weeks postpartum [12, 13]. Maternal and um-
bilical cord cytokine levels were a pre-specified second-
ary outcome of the study [12]. We used a random
number table maintained in the University of Michigan
Investigational Drug Pharmacy for random allocation.
Full details of the randomized, double-blinded study de-
sign as well as the primary and clinical outcomes have
been previously reported [12, 13].
There were 126 subjects enrolled in the parent study be-
tween October 2008 and May 2011. They were randomly
assigned to receive EPA rich fish oil (1060 mg EPA plus
274 mg DHA), DHA rich fish oil (900 mg DHA plus
180 mg EPA), or soy oil placebo and were followed longi-
tudinally through pregnancy from their enrollment at 12–
20 weeks’ gestation until 6 weeks postpartum. Maternal
blood was drawn at enrollment and again at 34–36 weeks
gestation. The minimum supplementation time was
14 weeks. Because of the double-dummy design of the
trial, all subjects received some placebo capsules. Umbil-
ical cord blood was obtained at delivery.
During the course of the study, eight subjects dropped
out and 118 subjects completed the study. There were
126 maternal samples available for cytokine analysis at
enrollment and 113 maternal samples available for ana-
lysis after supplementation (34–36 weeks). There were
102 cord blood samples available for analysis of cytokine
profiles. The flow diagram of participant enrollment and
sample availability is depicted Fig. 1.
Sample collection and biochemical assessment
We obtained venous blood after a four hour fast. Fetal cord
blood was collected at delivery. Cord blood was obtained
after severance of the umbilical cord by passive flow of
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mixed arterial and venous blood into EDTA-containing
tubes. All blood samples were processed by centrifugation
within 12 h of collection and the resultant plasma was
stored at − 80 °C [12, 13]. Multiplex immunoassays for cy-
tokines IL-1α, IL-1β, IL-2, IL-4,IL-5,IL-6,IL-8, IL-10,
IL-12p70, IL-13, IL-15, IL-17, IFNγ,MCP-1, TNFα, and
TNFβ were performed on plasma samples using the
Q-Plex™ Human Cytokine - Screen IR (16-plex), a fully
quantitative ELISA-based Infrared (IR) assay system
(Quansys Biosciences, Logan, UT).
Serum EPA and DHA, had been previously assayed
from sample collection of maternal and cord blood into
red top non-additive tubes at the same time points, with
DHA and EPA being evaluated as a measure of compli-
ance [13]. As we have previously reported, supplementa-
tion with the DHA-rich fish oil significantly increased
serum DHA levels in maternal and cord blood. Similarly,
supplementation with EPA-rich fish oil significantly in-
creased maternal serum EPA fraction but not cord blood
EPA. These variables were available from prior study to
evaluate as predictors of maternal and cord blood
plasma cytokine levels [13].
Ethics
The procedures followed were approved and conducted in
accordance with the institutional review boards of the
University of Michigan Medical Center, Ann Arbor, MI,
St. Joseph Mercy Hospital in Ypsilanti, MI, and The Uni-
versity of New Mexico Health Sciences Center Human
Research Protections Office. All subjects gave written in-
formed consent to participate in the study. The trial was
registered on 7/7/2008 at clinicaltrials.gov: NCT00711971
under the title: “Does Fish Oil Prevent Depression in Preg-
nancy and Postpartum”.
Statistics
For a simple post-hoc power analysis, we used our
change in maternal plasma IL-6 at visit 3 (34–36 weeks)
between EPA-rich fish oil and placebo. For our sample
size of 37 in the EPA group and 40 in the placebo group,
we could detect a group difference in the change in IL-6
of 80 pg/ml with 80% power and a significance of 0.05.
This power analysis was based on the standard devia-
tions (94 pg/ml and 176 pg/ml) that we observed in
these two groups. Although this study’s sample size was
Fig. 1 Consort 2010 Flow Diagram
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determined in order to evaluate a different primary out-
come measure (the Beck Depression Inventory score at
6 weeks’ postpartum), it had adequate power (80%) to
detect a group difference between the change in mater-
nal IL-6 after supplementation compared to placebo.
We computed median and interquartile range values for
the all of the cytokines at each of the time points. If the
value for a sample was reported as “below detectable
limits”, the value of half the lower limit of detection for
the cytokine was used for the purposes of subsequent
comparisons, a technique known as “single value imput-
ation” [14]. Cytokine concentrations were log-transformed
in order to symmetrize the skewed distributions. All ana-
lyses were according to intention to treat principles. For
all ANCOVA analyses that evaluated the effect of DHA-
and EPA- rich fish oil supplementation on maternal cyto-
kines, we adjusted for the baseline values of fatty acids
(EPA and DHA fractions) and cytokines by subtraction of
visit 1 values from visit 3 values. Where there was a sig-
nificant treatment effect, post hoc multiple comparisons
between the treatments was done by Fisher’s Least Signifi-
cant Difference method.
In addition, we adjusted for maternal BMI at enrollment
(visit 1). Because of the potential correlation of allocated
treatment group with EPA and DHA concentrations, the
model was analyzed with and without each of these vari-
ables. Pearson’s correlation coefficients were computed to
describe the relationship between serum EPA and DHA
fractions, maternal BMI and the cytokines under study.
We performed ANCOVA analyses to describe the rela-
tionship between the group of allocation and cytokines
in the umbilical cord blood. All analyses were adjusted
for exposure to labor (regardless of mode of delivery),
gestational age at delivery, birth weight, as well as DHA
and EPA concentrations in umbilical cord blood. Ana-
lyses were carried out with all variables in the model as
well as with correlated variables removed. Pearson cor-
relation coefficients were constructed to evaluated the
relationship between each of the variables in the model
and the cytokines under study in order to assess the
changes in cytokines between enrollment and late preg-
nancy pooled across groups, we computed the differ-
ences between visits 3 and visit 1 and compared to no
change using one sample t tests.
Results
Effect of fish oil supplementation on maternal cytokines
There were 126 samples available for maternal cytokine
analyses at enrollment and 113 samples available after
supplementation. The median and interquartile ranges
of the maternal cytokines at two time points are pre-
sented in Table 1.
There was no statistically significant change in the con-
centrations of the cytokines under study between early
and late pregnancy. We modeled the change in the cyto-
kines of interest between enrollment (12–20 weeks) and
after supplementation (34–36 weeks) with adjustment for
body mass index (BMI) at enrollment, DHA, EPA, and
group allocation. EPA-rich fish oil treatment decreased
plasma concentrations of IL6 (P = 0.02), IL 15 (P = 0.03),
and TNF α (P = 0.03) after adjustment for baseline cyto-
kine concentrations, and BMI. Treatment group was not
significantly related to the change in IL 1 β, IL2, IL5, IL8,
IL12P70, IL17, IFN γ, or MCP1 on post hoc multiple com-
parisons. We found no significant effect of the DHA-rich
fish oil treatment on cytokine concentrations, when com-
pared with placebo.
Our model evaluated the relationship of the variables
in the model with the cytokines of interest. We found a
positive association between maternal serum DHA frac-
tion, adjusted for DHA fraction at baseline, with IL 1 α
(P = 0.05) and with IL10, a cytokine with both pro- and
anti-inflammatory properties (P = 0.05) [15]. By contrast
EPA fraction was inversely (negatively) associated with
IL10 concentrations (P = 0.04). BMI at entry to the study
was inversely associated with TNF beta (P = 0.04). These
relationships are summarized in Table 2. These findings
were not altered when the correlated variable of study
group allocation as well as EPA and DHA fraction were
analyzed separately in the model.
For fetal (cord blood) cytokines, there were 102 cord
blood samples available for analysis. The median and
interquartile ranges of the cord blood cytokines are rep-
resented in Table 3. There were no significant differ-
ences in cord blood cytokines according to treatment
group. Cord blood DHA fraction was negatively correlated
with cord blood IL 1β (P = 0.03), a relationship that how-
ever did not persist after adjusting for labor and gesta-
tional age at delivery. There were no other significant
associations between EPA or DHA to concentrations of
any of the cytokines that we studied. Of other variables in-
cluded in the model, we found that gestational age was
positively correlated with IL8 (P = 0.05). When serum EPA
and DHA fraction were excluded from the model,
exposure to labor was positively correlated with IL10
(P = 0.04). There were no other significant relationships
demonstrated.
Discussion
We found that some maternal plasma cytokine concen-
trations may be significantly modulated by dietary sup-
plementation during pregnancy. Our study found that
supplementation with EPA-rich fish oil in particular re-
sulted in reduced concentrations of IL6 and TNFα, in-
flammatory cytokines that have been associated with
major depression in other studies [16]. These findings
are similar to the results of a randomized control trial of
supplementation with 2 g/day of omega-3 fatty acids
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Table 1 Maternal cytokine values before and after supplementation
LLD Enrollment 1 N = 126 Post-supplementation N = 113
median IQR median IQR
IL1α 6.664 EPA 6.66 (6.66,11.3) 6.66 (6.66,6.66)
DHA 6.66 (6.66,15.4) 6.66 (6.66,6.66)
Placebo 6.66 (6.66,6.66) 6.66 (6.66,10.6)
IL1β 7.806 EPA 13.2 (7.81,48.5) 15.7 (7.81,68.7)
DHA 7.81 (7.81,48) 16.3 (7.81,63.6)
Placebo 9.65 (7.81,46.7) 23 (7.81,74.2)
IL2 2.584 EPA 26.7 (2.58,64.1) 23.1 (6.4,57.9)
DHA 27.9 (6.1,71.4) 15.5 (2.58,48.1)
Placebo 30.5 (2.58,61.8) 28.2 (2.58,61.7)
IL4 0.776 EPA 0.776 (0.78,4.7) 0.776 (0.776,2.5)
DHA 0.776 (0.78,3.8) 0.776 (0.776,6.2)
Placebo 0.776 (0.78,3.7) 0.776 (0.776,2.15)
IL5 35.05 EPA 35.1 (35.1106) 35.1 (35.1107)
DHA 35.1 (35.1,48.4) 35.1 (35.1128)
Placebo 35.1 (35.1,67.9) 35.1 (35.1,95.2)
IL6 18.466 EPA 18.5 (18.5,41.8) 18.5 (18.5,23.6)
DHA 18.5 (18.5,18.5) 18.5 (18.5,50.2)
Placebo 18.5 (18.5,18.5) 18.5 (18.5,36.8)
IL8 9.894 EPA 9.89 (9.89,18.7) 9.89 (9.89,38.4)
DHA 9.89 (9.89,12) 9.89 (9.89,24.3)
Placebo 9.89 (9.89,9.89) 9.89 (9.89,26.9)
IL10 2.94 EPA 2.94 (2.94,48.3) 2.94 (2.94,32.5)
DHA 2.94 (2.94,37.3) 2.94 (2.94,57.4)
Placebo 2.94 (2.94,43.3) 2.94 (2.94,36.0)
IL12p70 45.458 EPA 45.5 (45.5,99.3) 45.5 (45.5108)
DHA 45.5 (45.5,71.7) 45.5 (45.5,76)
Placebo 45.5 (45.5154) 45.5 (45.5,94.1)
IL13 12.608 EPA 12.6 (12.6,55.3) 12.6 (12.6,29.2)
DHA 12.6 (12.6,58.6) 12.6 (12.6,42.8)
Placebo 12.6 (12.6,33.1) 12.6 (12.6,44)
IL15 7.734 EPA 7.73 (7.73,29.2) 7.73 (7.73,7.73)
DHA 7.73 (7.73,7.73) 7.73 (7.73,13.2)
Placebo 7.73 (7.73,7.73) 7.73 (7.73,25)
IL17 45.586 EPA 45.6 (45.6,49.7) 45.6 (45.6,45.6)
DHA 45.6 (45.6,45.6) 45.6 (45.6,45.6)
Placebo 45.6 (45.6,86.9) 45.6 (45.6,59.8)
IFNγ 58.506 EPA 58.5 (58.5104) 58.5 (58.5294)
DHA 58.5 (58.5156) 58.5 (58.5206)
Placebo 58.5 (58.5142) 58.5 (58.5159)
MPC1 5.686 EPA 125 (83.6224) 139 (82.6212)
DHA 118 (75.9228) 107 (60.2183)
Placebo 138 (88,183) 129 (75.1171)
TNFα 15.146 EPA 15.1 (15.1114) 15.1 (15.1,46.9)
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among obese pregnant women. In that trial, prenatal
supplementation was found to reduce inflammatory
markers in maternal adipose tissue and in the placenta
[17]. This finding is in contrast with previous observa-
tions among healthy non-pregnant adults in which sup-
plementation with fish oil up to 3.5 g/day had no
significant effect on cytokine profiles [10]. The reason
for this finding is unknown, but may relate to the unique
maternal immunology during pregnancy. Our findings
were consistent with previous reports which suggest that
EPA may be more effective than DHA in reducing in-
flammatory biomarkers [18].
By contrast, we found that fish oil supplementation in
doses of approximately 1 g/day had no significant effect
on umbilical cord blood cytokine concentrations. Our
findings are not consistent with a systematic review of
prior prenatal supplementation trials that found signifi-
cant reduction of IL13 in infants of mothers who took
prenatal fish oil supplementation [19]. This finding is
also in contrast to our previously reported secondary
analysis of the effect of fish oil supplementation on che-
mokine profiles among participants in this trial. That
analysis found that the EPA- and DHA-rich fish oil had no
significant effect on maternal chemokine concentrations,
but significantly influenced cord blood chemokine ratios
[20]. The reason for this discrepancy is unknown but may
be related to the number of cord blood samples with cyto-
kine concentrations that fell below detectable limits.
Based on our findings, we conclude that the fatty acid
content of the prenatal maternal diet may modulate the
maternal immune response, although prenatal supple-
mentation did not significantly affect cord blood cyto-
kine profiles in our study.
Strengths of our study included blinded assessment of
outcomes, randomized design, and intent-to-treat ana-
lyses. The study also had several limitations. These in-
cluded the differing times of day at which maternal
blood samples were procured, a result of study proce-
dures being timed with clinical care. However, all mater-
nal samples were drawn after a four hour fast with only
low-fat meals allowed on the day of the blood draw.
Another limitation of our study is that many cytokine
concentrations were below the limits of detection for the
assay used. These results were consistent with the results
from other studies analyzed in the same laboratory and all
of the study samples were analyzed on the same date.
Likewise, the sample size of our study was based on the
primary outcome of the Beck Depression Inventory score
at 6 weeks’ postpartum. Nevertheless, our post-hoc power
analysis suggests that this secondary study had reasonable
Table 1 Maternal cytokine values before and after supplementation (Continued)
LLD Enrollment 1 N = 126 Post-supplementation N = 113
median IQR median IQR
DHA 15.1 (15.1,15.1) 15.1 (15.1,41.5)
Placebo 15.1 (15.1,48.2) 15.1 (15.1,58.1)
TNFβ 4.956 EPA 4.96 (4.96,10.9) 4.96 (4.96,4.96)
DHA 4.96 (4.96,10.5) 4.96 (4.96,15.8)
Placebo 4.96 (4.96,16.5) 4.96 (4.96,4.96)
All values in pg/ml
IQR = inter quartile range
LLD = lower limit of detection
Range of values below detectable limits from 2.5 to 83.3%




Table 2 Variables predictive of maternal cytokine concentrations
Variable Cytokine Slope Standard error +/− Significance
EPA-rich fish oil group IL6 −76.3 32.2 0.02
EPA-rich fish oil group IL15 −23.8 10.9 0.03
EPA-rich fish oil group TNFα − 141.1 62.6 0.03
DHA fraction IL1α 4.64 2.33 0.05
DHA fraction IL10 4.82 2.36 0.04
EPA fraction IL10 −18.8 8.42 0.03
BMI at entry TNFβ −0.64 0.32 0.05
All analyses were adjusted for the following variables: Baseline concentrations of each cytokine, maternal BMI, maternal serum EPA fraction adjusted for baseline
and DHA fraction adjusted for study baseline
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power to detect a treatment effect of the fish oil supple-
mentation on cytokine concentrations.
Additionally, our study was also limited by its
double-dummy design which meant that all subjects in
the intervention groups received soy oil placebo capsules
along with the EPA- and DHA- rich fish oil capsules. Fi-
nally, it should be noted that the subjects were selected
based on predisposition to depression and may have not
been representative of the general population of preg-
nant women.
Conclusions
Our findings allow us to hypothesize that among women
with perinatal depressive symptoms related to inflamma-
tion, prenatal EPA-rich fish oil supplementation may re-
duce plasma concentrations of inflammatory cytokines.
Current research in depression is moving toward identifi-
cation of a subset of depressed individuals in whom dys-
regulated cytokine production may play a role in
pathogenesis. Future research should focus on the role of
omega-3 fatty acids, in particular EPA, in modulation of
the immune response in this population, and should work
to elucidate the relationship of inflammatory cytokines
with depressive symptomatology in these individuals.
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